
    
      For this randomly assigned to receive either a 14-day hybrid therapy (a dual therapy with
      pantoprazole 40 mg bid, amoxicillin 1 g bid for 7 days, followed by a quadruple therapy with
      pantoprazole 40 mg bid, amoxicillin 1 g bid, clarithromycin 500 mg bid, and metronidazole 500
      mg bid for a further 7 days) or a 14-day bismuth containing quadruple therapies (pantoprazole
      40 mg bid , bismuth subcitrate 120 mg qid., tetracycline 500 mg qid, and metronidazole 250 mg
      qid for 14 days).at a 1:1 ratio. Our primary outcomes was the eradication rate by
      intention-to-treat and per- protocol analyses
    
  